Incyte (INCY) Return on Capital Employed (2011 - 2026)
Incyte posted quarterly Return on Capital Employed of 28.47% for Q1 2026, up 2396.0% year-on-year from 1.14% in Q1 2025, and down 3.62% on a QoQ basis from 29.54% in Q4 2025.
Incyte (INCY) has 16 years of Return on Capital Employed data on file, last reported at 28.47% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2396.0% year-over-year to 28.47%; the trailing twelve-month figure through Mar 2026 stood at 28.47% (up 2396.0% YoY), and the FY2025 full-year result was 32.33%, up 3096.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 28.47%, down from 29.54% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 31.25% in Q3 2025 and bottomed at 1.59% in Q3 2024.
- The 5-year median for Return on Capital Employed is 12.36% (2024), against an average of 13.62%.
- The widest annual swing landed in 2024, when Return on Capital Employed plunged 1131 bps; it then jumped 3284 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 12.82% in 2022, then declined by 9 bps to 11.61% in 2023, then slumped by 85 bps to 1.71% in 2024, then surged by 1626 bps to 29.54% in 2025, then slipped by 4 bps to 28.47% in 2026.
- The last three Return on Capital Employed figures came in at 28.47% (Q1 2026), 29.54% (Q4 2025), and 31.25% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 28.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.47% |
| Dec 31, 2025 | 29.54% |
| Sep 30, 2025 | 31.25% |
| Jun 30, 2025 | 26.25% |
| Mar 31, 2025 | 4.50% |
| Dec 31, 2024 | 1.71% |
| Sep 30, 2024 | -1.59% |
| Jun 30, 2024 | 0.35% |
| Mar 31, 2024 | 12.36% |
| Dec 31, 2023 | 11.61% |
| Sep 30, 2023 | 9.73% |
| Jun 30, 2023 | 8.74% |
| Mar 31, 2023 | 10.13% |
| Dec 31, 2022 | 12.82% |
| Sep 30, 2022 | 14.07% |
| Jun 30, 2022 | 16.83% |
| Mar 31, 2022 | 14.69% |
| Dec 31, 2021 | 15.78% |
| Sep 30, 2021 | 19.32% |
| Jun 30, 2021 | 13.10% |
| Mar 31, 2021 | 16.71% |
| Dec 31, 2020 | -9.41% |
| Sep 30, 2020 | -12.54% |
| Jun 30, 2020 | -8.41% |
| Mar 31, 2020 | -12.99% |
| Dec 31, 2019 | 31.23% |
| Sep 30, 2019 | 19.88% |
| Jun 30, 2019 | 7.28% |
| Mar 31, 2019 | 7.08% |
| Dec 31, 2018 | 1.12% |
| Sep 30, 2018 | 2.04% |
| Jun 30, 2018 | 1.65% |
| Mar 31, 2018 | -2.24% |
| Dec 31, 2017 | -5.57% |
| Sep 30, 2017 | -10.45% |
| Jun 30, 2017 | -12.71% |
| Mar 31, 2017 | -9.99% |
| Dec 31, 2016 | 2.85% |
| Sep 30, 2016 | 8.30% |
| Jun 30, 2016 | 9.19% |
| Mar 31, 2016 | 5.33% |
| Dec 31, 2015 | 0.33% |
| Sep 30, 2015 | -4.44% |
| Jun 30, 2015 | 4.26% |
| Mar 31, 2015 | 1.85% |
| Dec 31, 2014 | -0.84% |
| Sep 30, 2014 | -1.35% |
| Jun 30, 2014 | -16.30% |
| Mar 31, 2014 | -8.84% |
| Dec 31, 2013 | -7.52% |
| Sep 30, 2013 | 5.79% |
| Jun 30, 2013 | 7.30% |
| Mar 31, 2013 | 7.00% |
| Dec 31, 2012 | -8.71% |
| Sep 30, 2012 | -43.96% |
| Jun 30, 2012 | -64.53% |
| Mar 31, 2012 | -95.60% |
| Dec 31, 2011 | -66.76% |
| Sep 30, 2011 | -30.01% |
| Jun 30, 2011 | -18.90% |
| Mar 31, 2011 | -1.96% |